We're hosting a Patient-Led Research Fund (PLRF) webinar on July 9, 1–4:30PM ET!
Hear results from 10 PLRF-funded biomedical studies (on microclots, T cell exhaustion, trials, & more), all selected by a panel of patient-researchers.
The facts cover the basics, as well as current information on incidence, reinfections, research, and lesser known topics.
To start:
Long COVID is a global public health crisis, affecting over 400 million people worldwide. 2/
Long COVID is common. As of fall 2024, at least 1 in 19 US adults are currently living with Long COVID - similar to the rate of diabetes - with many additional cases likely going undiagnosed or misdiagnosed. 3/
We’re happy to announce a new @patientled preprint out today, on machine learning phenotypic with high-dimensional #LongCovid symptom data!
We used a dataset of 162 symptoms in 6,031 participants to explore making clusters of Long Covid patients. 1/ researchsquare.com/article/rs-490…
In sum, we used three different machine learning methods (a genetically optimized deep learning model, ensemble clustering, and probabilistic modeling).
We found that consistent clusters were *not* discovered across the three methods. 2/
This implies both that:
a) symptoms may not be the best way to create phenotypes of #LongCovid patients
b) studies that use fewer symptoms, fewer patients, or only use a single clustering methodology might be detecting phenotypes that are not robust or repeatable
3/
Those who had 2 COVID infections were 2.14 times more likely, and those who had 3 or more COVID infections were 3.75 times more likely, to report #LongCOVID than those with one infection.
2/
The odds of both severe fatigue and post-exertional malaise, two debilitating symptoms, increased with reinfections. 3/ #LongCovid
Population-wide, 10.4% of people with pre-existing disabilities had #LongCovid as of summer 2022, vs 7.5% without. 2/
The prevalence of #LongCovid was highest in those with chronic illness (diabetes, asthma) & lowest in those with sensory disabilities (deafness, blindness).
With the exception of sensory disabilities, all disability categories had higher LC rates than the general population. 3/
We’ve released a new paper on designing & optimizing clinical trials for #LongCOVID!
Strong, high-impact trials are critical & most current ones are insufficient. The paper gives guidance on treatments, outcomes, design, participant inclusion, & more.
It also gives an overview of the promising interventions being trialed (as of May 2024) for #LongCovid and their targets, including viral persistence, immune dysfunction, endothelial dysfunction, and symptom management. 2/
Some other key points:
-Trials should prioritize potentially curative interventions, including repurposed drugs and the development of new drugs.
-Combinations of therapies may be beneficial or necessary, which should be considered in clinical trial design. 3/
We are happy to announce a new #LongCovid review out in Nature!
This was led by @zalaly, with co-authors @leticiasaurus @LisaAMcCorkell and @ahandvanish from PLRC, alongside @VirusesImmunity, @EricTopol, and @swulfie.